In order to assess if the results we found in 3 mutationally diverse AML cell lines can be replicated in primary AML patient samples, we obtained cryopreserved samples from patients with AML who were verified to be HLA-A*02:01 positive by DNA genotyping and had high blast counts (sample characteristics summarized in Table 1). This evidence concerns the gene HLA-A and acute myeloid leukemia.